End of preview. Please join Docstoc to see the entire document.
Genizon BioSciences, Inc. (Genizon) is involved in the genetic biomarker discovery. The company discovers genes and biomarkers in common diseases using genome-wide association studies (GWAS). The services offered by the company include SNP genotyping, genetic analysis, gene expression, and pharmacogenomics services. The company focuses on genome-wide association studies for rheumatoid arthritis, Alzheimer’s disease, and coronary heart disease and its precursors, obesity, type II diabetes, dyslipidemia and hypertension. Genizon out-licensed some of its therapeutic and diagnostic rights to GeneMaps for Crohn’s disease and endometriosis and Alzheimer’s disease to Pfizer. GeneMaps are also generated from GWAS in schizophrenia, psoriasis and longevity. Also, the company holds licensing partnership with Genentech. The company signed an agreement with London Genetics Ltd through which both the companies will collaborate to replicate discoveries generated by Genizon in a genome-wide association study of schizophrenia. Recently, Genizon partnered with Speid & Associates to increase success rates of new drug compounds with the use of Genizon's proprietary genetic platform. Genizon BioSciences, Inc. is headquartered in Quebec, Canada.